Myriad Genetics (NASDAQ: MYGN) CCO has shares withheld to cover RSU taxes

Rhea-AI Filing Summary

MYRIAD GENETICS INC Chief Commercial Officer Brian J. Donnelly had 55,975 shares of Common Stock withheld at $4.80 per share to cover tax obligations. These shares were withheld in connection with the vesting of previously granted restricted stock units, and he now directly holds 568,363 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Donnelly Brian J

Role Chief Commerical Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	55,975	$4.80	$269K

Holdings After Transaction: Common Stock — 568,363 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 55,975 shares Withholding price per share: $4.80 per share Shares held after transaction: 568,363 shares

3 metrics

Shares withheld for taxes 55,975 shares Common Stock withheld to satisfy tax obligations on RSU vesting

Withholding price per share $4.80 per share Based on closing price on May 1, 2026

Shares held after transaction 568,363 shares Direct MYGN Common Stock holdings after tax-withholding disposition

Key Terms

restricted stock units, tax withholding obligations, withheld by the Issuer

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units previously granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting"

withheld by the Issuer financial

"Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donnelly Brian J

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commerical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		F		55,975(1)	D	$4.8	568,363	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on May 1, 2026.

Remarks:

	By: Justin Hunter For: Brian J. Donnelly	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MYGN executive Brian J. Donnelly report?

Brian J. Donnelly reported a tax-withholding disposition of 55,975 MYGN Common Stock shares. The shares were withheld by the company to satisfy tax obligations tied to vesting restricted stock units, rather than an open-market sale.

Was the MYGN insider transaction an open-market sale of shares?

No, the MYGN insider transaction was not an open-market sale. Shares were withheld by the issuer to cover tax withholding obligations from vesting restricted stock units, a routine administrative event rather than a discretionary sale in the market.

At what price were MYGN shares withheld for Brian J. Donnelly’s taxes?

The 55,975 MYGN shares were withheld at $4.80 per share. The number of shares withheld was based on the closing price of Myriad Genetics’ Common Stock on May 1, 2026, when the restricted stock units vested.

How many MYGN shares does Brian J. Donnelly hold after this transaction?

After the tax-withholding disposition, Brian J. Donnelly directly holds 568,363 MYGN Common Stock shares. This figure reflects his remaining position following the shares withheld by the company to satisfy his tax obligations on vested restricted stock units.

Why were MYGN shares withheld from Brian J. Donnelly’s restricted stock unit vesting?

MYGN shares were withheld to satisfy Brian J. Donnelly’s tax withholding obligations when his restricted stock units vested. Instead of paying cash for taxes, part of the vested shares was automatically retained by the issuer at the stock’s closing price.